Conley Chee sold $27k of SYRS
President & CEO at Syros Pharmaceuticals, Inc.. 134,797 shares at an average of $0.20, traded Nov 18, 2024, filed Nov 20, 2024.
Score components
- +25RoleCEO
- +5Trade size$27k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -31.0%, 3m -38.1%, 6m -89.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-129380, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | SOpen-market sale Common Stock | -134,797 | $0.20 | $27k | 0 | Nov 20, 2024 |
Related signals
Other insiders at Syros Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Syros Pharmaceuticals, Inc. | Nancy A Simonian President & CEO | $10k 37,070 shares | -90% | |
| 56Moderate | Syros Pharmaceuticals, Inc. | Nancy A Simonian President & CEO | $36k 134,713 shares | -77% | |
| 62Notable | Syros Pharmaceuticals, Inc. | Jason Haas Chief Financial Officer | $29k 137,803 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | Gerald E Quirk Chief Legal & Compliance Offic | $10k 46,657 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | David Roth Chief Medical Officer | $2,382 12,099 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | Kristin Stephens Chief Development Officer | $7,949 36,133 shares | -100% | |
| 60Notable | SYRSbuy Syros Pharmaceuticals, Inc. | Srinivas Akkaraju director | $4.0M 904,977 shares | +103% | |
| 20Weak | Syros Pharmaceuticals, Inc. | David Roth Chief Medical Officer | $31k 6,287 shares | -100% | |
| 15Weak | Syros Pharmaceuticals, Inc. | David Roth Chief Medical Officer | $25k 6,287 shares | -50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.